Evidence map›Paper›PMID 38670795›Full record

ArticleTobacco control2025

2020 design and methods of the Population Assessment of Tobacco and Health (PATH) study during the COVID-19 pandemic.

Ralph DiGaetano, Sylvia Dohrmann, Ethel V Taylor, Colm D Everard, Victoria Castleman, Ting Yan, Heather L Kimmel, Izabella Zandberg, Andrea Piesse, Jean D Opsomer and 16 more

Abstract read
In one paragraph

Article in Tobacco control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Ralph DiGaetanoWestat Inc, Rockville, Maryland, USA.
Sylvia DohrmannWestat Inc, Rockville, Maryland, USA sylviadohrmann@westat.com.ORCID 0009-0009-9058-9421
Ethel V TaylorCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Colm D EverardNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Victoria CastlemanWestat Inc, Rockville, Maryland, USA.
Ting YanWestat Inc, Rockville, Maryland, USA.
Heather L KimmelNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Izabella ZandbergCenter for Scientific Review, National Institutes of Health, Bethesda, Maryland, USA.
Andrea PiesseWestat Inc, Rockville, Maryland, USA.
Jean D OpsomerWestat Inc, Rockville, Maryland, USA.ORCID 0000-0002-9508-5021
Nicolette BorekCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Marushka L SilveiraKelly Government Solutions, Rockville, Maryland, USA.ORCID 0000-0002-4880-2550
Frost HubbardWestat Inc, Rockville, Maryland, USA.
Kristie TaylorWestat Inc, Rockville, Maryland, USA.ORCID 0000-0001-6668-7923
MeLisa R CreamerNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Anikah H SalimCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Eva SharmaWestat Inc, Rockville, Maryland, USA.ORCID 0000-0002-1328-508X
Yu-Ching ChengCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Victoria VignareWestat Inc, Rockville, Maryland, USA.
Tammy CookWestat Inc, Rockville, Maryland, USA.
Wioletta Szeszel-FedorowiczCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Yumiko SiegfriedWestat Inc, Rockville, Maryland, USA.
Charles CarusiWestat Inc, Rockville, Maryland, USA.
Debra StarkCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Silvana SkaraCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, USA.
Andrew HylandRoswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Funding

NIDA NIH HHS HHSN271201100027CNIDA NIH HHS HHSN271201600001C
6 · The paper itself

Abstract

The Population Assessment of Tobacco and Health (PATH) Study is a nationally representative, longitudinal study of the US population on tobacco use and its effects on health, collecting data annually since 2013. The COVID-19 pandemic interrupted in-person survey data collections around the world. In the USA, this included a PATH Study data collection focused on youth (13-17) and young adults (18-19) as well as other US surveys on tobacco use. Given that it was necessary to pause data collection and considering that tobacco-use behaviours could be expected to change along with pandemic-related changes in the social environment, the original design for the 2020 PATH Study data collection for youth and young adults was modified. Also, the PATH Study Adult Telephone Survey was developed to address the need for adult tobacco use monitoring in this unprecedented time. This article describes the modifications made to the 2020 PATH Study design and protocol to provide nationally representative data for youth and adults after the onset of the COVID-19 pandemic as well as the implications of these modifications for researchers.

Indexed as

COVID-19Research DesignTobacco UseAdolescentAdultFemaleHealth SurveysHumansLongitudinal StudiesMalePandemicsSARS-CoV-2United StatesYoung AdultCOVID-19Electronic nicotine delivery devicesSurveillance and monitoring

Identifiers

PMID38670795
PMCPMC11511785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.